Resapp Health : Update on Field Evaluation by Medecins Sans Frontieres

ASX / MEDIA RELEASE Update on Field Evaluation by Médecins Sans Frontières/Doctors Without Borders Brisbane, Australia, 14 September 2017 -- ResApp Health Limited (ASX:RAP), a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease, today provided an update on the planned field evaluation of ResAppDx by Médecins Sans Frontières/Doctors Without Borders (MSF). Key staff at MSF have reaffirmed their belief in the potential of ResApp's core technology, however after reviewing the issues identified by ResApp in its SMARTCOUGH-C study, and the high cost of keeping the project open, MSF will not proceed with its planned field evaluation of ResAppDx at this point in time. ResApp is currently focused on its restart of the US SMARTCOUGH-C paediatric clinical study this US winter, which includes an array of enhanced procedures and features developed in collaboration with the participating US hospitals. ResApp and MSF will maintain their collaborative relationship and seek opportunities for field testing the technology once issues identified in the SMARTCOUGH- C study have been resolved. About ResApp Health Limited

ResApp Health Limited (ASX: RAP) is a digital health company developing smartphone applications for the diagnosis and management of respiratory disease. The technology is based on machine learning algorithms that use cough sounds to diagnose and measure the severity of respiratory conditions without the need for additional hardware. The algorithms were initially developed by The University of Queensland with funding from the Bill and Melinda Gates Foundation. ResApp has adult and paediatric clinical studies underway at leading US and Australian hospitals with results demonstrating accurate diagnosis of pneumonia, asthma/reactive airways disease, bronchiolitis, croup and upper respiratory tract infections in children as well as chronic obstructive pulmonary disease, asthma, pneumonia and upper respiratory tract infections in adults. Potential customers of ResApp's products include healthcare providers in telehealth, emergency department, urgent care and primary care settings as well as global aid and humanitarian organisations in the developing world.

For more information on ResApp, visit www.resapphealth.com.au

Contacts

Dr Tony Keating

CEO and Managing Director

[phone]

[e-mail]

Mr Brian Leedman Executive Director and

Vice President, Corporate Affairs

[phone]

[e-mail]